พัฒนาการทันยุคการรักษามะเร็งตับอ่อนในปี 2005

Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403-13.

Rothenberg ML, Moore MI, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5- FU-refractory pancreas cancer. Ann Oncol. 1996; 7: 347-53.

Abbruzzese JL, Grunewald R, Weeks EA, et al: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. I Clin Oncol 1991; 491-498.

Von Hoff DD: Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with Gemcitabine: San Antonio Drug Development Team. Invest New Drugs 1996; 14: 265-270.

Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randornized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adeno- carcinoma. J Clin Oncol. 2003; 15: 3402-8.

Berlin ID, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastem Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-5.

Richards D, Kindler H, Oettle H, et al. A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. Proc Am Soc Clin On col 2004, Abstract 4007.

Riess H, Helm A, Niedergethmann M, et al. A Randomised, Prospective, Multicenter, Phase III Trial of Gemcitabine, 5-Fluorouracil (5-FU), Folinic Acid vs. Gemcitabine alone in Patients with Advanced Pancreatic Cancer. Proc Am Clin Oncol 2005, Abstract 4009.

Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase IIII study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). Proc Am Clin Oncol 2005, Abstract 4010.

Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004; 22: 3776-83.

P.Cheverton P, H. Friess H, C. Andras C, et al. Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 2004, Abstract 4005.

O Reilly E, Abou-Alfa G, Letourneau R, et al. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 2004, Abstract 4006.

Louvet C, Labianca R, Hammel P, et al. GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: Final results of the GERCOR/GISCAD Intergroup Phase III. Proc Am Soc Clin Oncol 2004, Abstract 4008.

H. L. Kindler, G. Friberg, M. Stadler, et al. Bevacizumab plus gemcitabine is an active combination in patients with advanced pancreatic cancer: Interim results of an ongoing phase II trial from the University of Chicago Phase II Consortium. Proc 2004 Gastrointestinal Cancers Symposium, Abstract 86.

Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004; 15: 1430-8.

Brumhall SR, Schulz J, Nemunaitis I, et al. A double~ blind placebo-controlled, randomised study comparing gencitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002; 15;87: 161-7.

Moore M, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc Am Clin Oncol 2005, Abstract 1.

Neoptolemos JP, Cunningham D, Friess H, et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol. 2003;14:675-692.

Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (600000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5- fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981; 48: 1705-10.

Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004 Mar 18; 350(12): 1200-10.

Neuhaus P, Oetle H, Post S, et al. A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. Proc Am Clin Oncol 2005, Abstract 4013.